A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”).

Grant

Date/time Interval

  • July 1, 2018 - May 31, 2022
  • Awarded By

    Total Award Amount

  • 181194.00
  • Direct Costs

  • 122016.00
  • Sponsor Award Id

  • WU-19-282
  • Contributor

  • Aparna Singhal   Investigator  
  • Bryan Smelser   Investigator  
  • David Geldmacher   Investigator  
  • Erik Roberson   Principal Investigator  
  • Marissa Natelson Love   Investigator  
  • Philip Chapman   Investigator